These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 33836789)

  • 1. SUV
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Kemuriyama K; Sasaki Y; Imai K; Maeda E; Minamiya Y
    Ann Surg Oncol; 2022 Feb; 29(2):1336-1346. PubMed ID: 34355333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.
    Suzuki T; Okamura A; Watanabe M; Mine S; Imamura Y; Asari T; Osumi H; Nakayama I; Ichimura T; Ogura M; Ooki A; Takahari D; Yamaguchi K; Chin K
    Ann Surg Oncol; 2020 May; 27(5):1510-1517. PubMed ID: 31820213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy.
    Kurokawa T; Hamai Y; Emi M; Ibuki Y; Yoshikawa T; Ohsawa M; Hirohata R; Okada M
    Anticancer Res; 2020 Aug; 40(8):4387-4394. PubMed ID: 32727767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Saeki H; Nakashima Y; Zaitsu Y; Tsuda Y; Kasagi Y; Ando K; Imamura Y; Ohgaki K; Ito S; Kimura Y; Egashira A; Oki E; Morita M; Maehara Y
    Surg Today; 2016 Mar; 46(3):261-7. PubMed ID: 25740123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
    Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
    World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
    Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
    Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Kim JY; Yun JK; Kim YH; Park SI; Lee JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Kim SB; Cho KJ; Ryu JS; Kim JH; Kang J; Park SR; Kim HR
    Ann Surg Oncol; 2024 Oct; 31(10):6662-6672. PubMed ID: 38954089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.
    Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Isozaki Y; Akanuma N; Uno T; Matsubara H
    J Surg Oncol; 2012 Jun; 105(8):756-60. PubMed ID: 22162007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
    Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nodal Downstaging of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy: Survival Analysis if ypN0 Is Achieved.
    Tang H; Tan L; Wang H; Shen Y; Yin J
    J Gastrointest Surg; 2020 Jul; 24(7):1469-1476. PubMed ID: 31346888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy.
    Hirohata R; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Ohsawa M; Kitasaki N; Okada M
    World J Surg; 2024 Jul; 48(7):1700-1709. PubMed ID: 38757868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer.
    Motoyama S; Sato Y; Sasaki T; Wakita A; Kawakita Y; Liu J; Nagaki Y; Saito H; Imai K; Konno H; Mizusawa KT; Minamiya Y
    Anticancer Res; 2017 Oct; 37(10):5837-5843. PubMed ID: 28982909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
    Fujiwara Y; Yoshikawa R; Kamikonya N; Nakayama T; Kitani K; Tsujie M; Yukawa M; Inoue M; Yamamura T
    Oncol Rep; 2012 Aug; 28(2):446-52. PubMed ID: 22664791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.